Last reviewed · How we verify
NCT05394987: SPECTRA
Optical Correction and Visual Functions of Adults With Amblyopia
NA trial testing Spectacles in Amblyopia in 36 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | Centre for Eye and Vision Research |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 13 June 2022 |
| Primary completion | 30 November 2026 |
| Estimated completion | 31 May 2027 |
| Sites | 2 locations across Hong Kong, Canada |
Drugs / interventions tested
- Spectacles
Conditions studied
- Amblyopia — all drugs for Amblyopia →
Sponsor
Centre for Eye and Vision Research
Who can join
Adults 18 to 39, any sex, with Amblyopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Amblyopia is a developmental anomaly resulting from abnormal visual experiences in early life. Amblyopia causes reduced visual acuity in the absence of a pathology. Adult sensory systems are believed to be structurally invariant beyond early, critical periods of development. However, recent evidence suggest that visual functions in adults with amblyopia can be improved with optical correction alone. This study aims to investigate whether improvements in best corrected visual acuity and other visual functions can result following appropriate optical correction in adults with amblyopia. Functional measures relating to vision, binocular vision, and eye movements will be used to assess the efficacy of refractive correction for improving vision. This study will help us better understand the improvements in visual functions following optical correction, as well as the mechanisms underlying neuroplasticity in adults with amblyopia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
SPEctacle Correction for the TReatment of Amblyopia (SPECTRA): study protocol for a prospective non-randomised interventional trial in adults with anisometropic/mixed mechanism amblyopia.
Tan KWS, Park ASY, Cheung BWS, Wong GHT, et al · · 2024 · cited 1× · PMID 38950991 · DOI 10.1136/bmjopen-2023-080151
Verify or expand the search:
- PubMed search for NCT05394987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Spectacles
Trials testing the same drug.
- NCT06023108 — Assess the Effects of Spectacles or Orthokeratology on Dry Eye Parameters in Children and Adolescents. · NA · unknown
- NCT04629820 — PROductivity Study of Presbyopia Elimination in Rural-dwellers II · NA · recruiting
- NCT05538182 — Zimbabwe Eyecare And Learning(ZEAL):Formative Research on Hyperopia and Educational Outcomes in Primary School Children · NA · completed
- NCT04654013 — PROductivity Study of Presbyopia Elimination in Rural-dwellers III · NA · active not recruiting
- NCT04813640 — Eye Length Signal With Myopia Control · NA · unknown
Other recruiting trials for Amblyopia
Currently open trials in the same condition.
- NCT07323953 — Evaluation of AmblyoFix for the Treatment of Unilateral Amblyopia in Children · NA · recruiting
- NCT07281742 — Amblyopia Treatment for Children Aged 8 to 12 Years · NA · recruiting
- NCT07417046 — Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopi · NA · recruiting
- NCT06524882 — Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age · Phase 3 · recruiting
- NCT06380517 — Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age · Phase 3 · recruiting
Other Centre for Eye and Vision Research trials
Trials by the same sponsor.
- NCT05913063 — Direct Discrimination of Quantum States by the Human Eye · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05394987 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Eye and Vision Research
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05394987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing